PSM News

July 24,2024 New Delhi: The Centre should consider infertility a national health priority and include it under insurance, Dr Ajay Murdia, founder and chairman of Indira IVF, said, emphasising the need for investment in IVF infrastructure, especially in rural areas. The stark financial divide and monetary burden of seeking IVF treatments in India render it inaccessible for many, Dr Murdia told PTI on the eve of the World IVF Day, observed on July 25. He said the Ayushman Bharat scheme has greatly enhanced healthcare access for millions of Indians through financial protection and essential medical coverage. IVF treatment, if included in this scheme, could benefit millions of people by making essential services more accessible and affordable for those in need. According to some estimates, about 27.5 million married couples who are actively trying to conceive are suffering from infertility. But only about 275,000 IVF cycles are performed every year, Murdia, the man behind India’s one of the largest fertility chains said, citing available data. “This silent epidemic, affecting one in six couples, is rapidly evolving into a national emergency with far-reaching consequences for India’s societal structure and economic prospects,” he stated during the exclusive interview to PTI. The financial toll of this crisis is devastating, he rued. The IVF treatments, costing up to Rs 2-3 lakh per cycle, are pushing countless families into debt. Across the country, there’s a severe shortage of government-run IVF centres, effectively denying millions the chance of parenthood, Dr Murdia highlighted. Many state-funded health centres still lack the necessary facilities to provide effective infertility treatment. Private sector initiatives, such as establishing more IVF clinics in rural areas and providing financing options for treatment, are critical to bridging this gap, he pointed out. Diagnostic facilities and basic infertility investigations are limited in primary health centres (PHC)in rural regions, leading many to opt for traditional or religious practices instead of modern medical interventions, the Indira IVF founder said. The infertility treatment landscape paints a stark picture of inequality, he said. “This glaring healthcare gap is creating a dangerous divide where eventually only the wealthy can afford to build families,” he stated. “Around half of the country’s 2,500 IVF centres operate without a structured framework, which can impact the consistency of treatment quality. Moreover, a substantial portion of treatments is concentrated in urban areas, leaving rural populations with limited access to these services and creating significant gaps in fertility care availability,” Murdia said. The inclusion of comprehensive insurance coverage for infertility treatments, particularly IVF, could alleviate the financial strain on couples and make these essential services more accessible, he said. Insurance policies covering fertility treatments can bridge the financial divide, ensuring that all couples, regardless of their economic status, have an equal opportunity to build their families. Although EMI options are available for infertility treatments, Indian corporates offer insurance for IVF treatments. The government should consider this too, Murdia said. Currently, only CGHS employees and some other states provide IVF insurance, reimbursing Rs Rs 60,000-65,000 per cycle for up to three cycles, he said. The government needs to revise these costs to make them more acceptable to IVF centres until there is widespread government infrastructure with IVF facilities across the country, he added. According to NFHS, the fertility rate is 1.6 in urban areas and 2.1 in rural India. By 2050, India’s total fertility rate (TFR) is projected to dip irreversibly to 1.29, far lower than the replacement rate of 2.1. Investment in IVF infrastructure, especially in rural areas, is crucial, Dr Murdia underscored. Source: Healthworld

July 24,2024 New Delhi: The government is considering a proposal to do away with quality tests for cough syrups manufactured in plants approved by the regulatory authorities of developed markets, according to people aware of the development. The proposal, which follows a representation from a stakeholder, suggests that testing at the prescribed laboratory may be waived for cough syrups being exported to the US, UK, Canada, EU, Japan, Australia, Singapore, Republic of Korea and Switzerland. It has also been proposed that if the cough syrup is manufactured in a plant/section approved by the regulatory agencies of these countries for any product, such cough syrups may also be allowed to be exported to any country without testing. According to a recent report of the Central Drugs Standard Control Organisation (CDSCO), cough syrup samples collected from more than 100 pharma units in the country had failed quality tests and had the same toxins that were found in the cough syrups that were linked to deaths of children in Gambia, Uzbekistan and Cameroon. The sub-standard batches were declared as “not of standard quality” (NSQ) for parameters such as diethylene glycol (DEG) or ethylene glycol (EG), it said. Earlier, the government had notified that cough syrups manufactured in India can be exported only if they pass quality tests conducted by approved laboratories and on production of certificate of analysis. “The Cough syrups were permitted to be exported only after the samples were declared as of standard quality by any of the above laboratories,” the CDSCO said. Several laboratories, including government-run and private labs across the country, have since been conducting tests in the aftermath of reports linking India-made cough syrups to 141 child fatalities globally. In May last year, the Drug Controller General of India (DCGI) had asked state drug controllers “to give instructions to their state-owned NABL-accredited laboratories to analyse the samples received from the manufacturers of cough syrups for export purpose on top priority and issue the test report at the earliest”. The Directorate General of Foreign Trade (DGFT), too, had issued a similar order. To strengthen the checks, the CDSCO, with the help of state drug control departments, has been carrying out inspections of the cough syrup manufacturing units and distributors of propylene glycol to map the supply chain. Source: Healthworld

July 25,2024 New Delhi: The Budget proposal to waive customs levy on three specific cancer therapies has sparked claims of being “an eye-wash” and “selective”, as it covers only drugs from one MNC AstraZeneca. The exemption does not extend to the entire category or class of cancer drugs, and provides a “marginal” benefit averaging Rs 18,000 each per vial/strip, industry experts told TOI. Reacting to the move, AstraZeneca scrip jumped over 13 per cent over the last two days (from the July 22 close) to Rs 7,076 on the BSE. The proposal has renewed demands from industry and patient groups, and domestic pharma biggies like Biocon, for removal of GST on cancer and rare disease drugs, arguing that broader tax relief would more effectively support patients and the healthcare system. Further, the customs duty waiver should be extended to all imported cancer and rare disease drugs, and not be restricted to only one category, an executive with a MNC firm said. The Budget exempted three cancer drugs – Trastuzumab Deruxtecan, Osimertinib and Durvalumab – from a customs levy of 10 per cent . Trastuzumab Deruxtecan is a breast cancer drug, Osimertinib lung cancer and Durvalumab is used as lung and biliary tract cancer therapy. Kiran Mazumdar Shaw, chairperson, Biocon and Biocon Biologics said: “The removal of customs duty on three cancer drugs will provide relief to cancer patients. However, govt needs to consider GST exemption for all cancer drugs to make cancer care more affordable for patients.” At present, patients face a double whammy with the customs duty levy of 10 per cent , and a GST of 12 per cent, significantly hiking treatment costs of imported drugs. “We will renew the request for a waiver of customs duty on all cancer and rare disease drugs and a reduction of GST on drugs,” a Ficci representative said. Source: Pharma

July 25,2024 Munich: Three people effectively cured of HIV have spoken about how a risky transplant procedure saved their lives, with one saying they are “living proof” of hope in the fight against the virus. The trio spoke about their experience at the International AIDS Conference in Munich, which has gathered experts, researchers and activists to discuss developments in the HIV epidemic. Only seven people are considered to have been effectively cured after receiving a stem cell transplant, a painful and risky procedure only suitable for patients who have both HIV and aggressive leukaemia. Adam Castillejo, a 44-year-old also known as the “London patient”, told AFP that it took “years” to be sure that his transplant had had the desired effect. “There is not a specific time when you say: ‘You’re cured’, it takes a while and then you have controlled expectations towards that.” Only once doctors are sure that the patients’ HIV will not return do they stop treatment with antiretroviral drugs, which reduce the amount of the virus in the blood. “The doctors did so many tests to really be 100 percent sure before the antiretroviral therapy was discontinued,” Franke said. The bone marrow transplant, which carries a 10 percent risk of death, essentially replaces a person’s immune system. Pointing to the “enormous” mortality rate and other complications, Franke went so far as to say: “I can’t recommend it to anyone.” Despite having “lost several years” to leukaemia, Franke said in retrospect he “would have preferred to take one tablet a day” of antiretrovirals than to have gone through the gruelling transplant process. Earlier this month doctors announced the number of people effectively cured from HIV had reached seven. The seventh — dubbed the “next Berlin patient” — received a bone marrow transplant for his leukaemia in 2015 and stopped taking antiretroviral drugs in late 2018. Medical researchers said he now appears to be both HIV and cancer free. Sharon Lewin, President of the International AIDS Society, called the cases “really exciting” but admitted that the therapy was only applicable to a very small number of people. The procedure had effectively cured just “seven people out of 40 million people living with HIV”, Lewin said. “These are very rare cases, but they inspire new directions in science.” All but one of the seven patients received stem cells from donors who had a rare gene mutation which effectively makes people immune to HIV. Paul Edmonds is in his late sixties and was the third patient who spoke about his experiences at the conference. He agreed that “the stem cell transplant is not for everyone because there’s so many risks involved”. However Edmonds said his and his fellow patients’ experience gave “hope… that a cure is possible because we’re living proof that it can happen”. There were 1.3 million new HIV infections last year, while 39 million people are living with the virus, according to the World Health Organisation. Timothy Ray Brown — the original “Berlin patient” — was the first person declared cured of HIV back in 2008. Brown died from cancer in 2020. Source: Healthworld

July 25,2024 London: Anglo-Swedish drugmaker AstraZeneca raised its full year sales and profit forecast on Thursday after beating analyst expectations for second-quarter revenue on strong demand for its cancer, rare disease and heart disease medicines. Sales in AstraZeneca’s top business, oncology, grew 19 per cent at constant currency rates to $5.33 billion and accounted for 41 per cent of the total, while its rare disease and heart and kidney disease divisions also each raked in double-digit growth. Second-quarter profit though was dented by a rise in expenses and sales of cancer drugs Enhertu and Imfinzi were slightly softer than expected, analysts said. The shares slipped 3.6 per cent by 0830 GMT after gains of about 14 per cent so far this year. British rival GSK’s shares are up 4.1 per cent this year and Swiss drugmaker Roche is up 11 per cent this year, compared with the STOXX 600 Index gains of 7 per cent . AstraZeneca expects both 2024 revenue and core earnings per share to increase by a mid-teens percentage at constant currency rates, it said. It had previously expected revenue and profit to increase by a low double-digit to low-teens percentage. The UK’s most valuable company in terms of its market capitalisation of 189.4 billion pounds ($243.89 billion) has evolved significantly since CEO Pascal Soriot took over 12 years ago. New technologies such as antibody-drug conjugates are making up a rising proportion of its future cancer therapies. The sales outlook reflects how the company has moved beyond the COVID vaccine, its best-selling product at the height of the pandemic in 2021, thanks to its roster of cancer therapies and a strong pipeline, including new treatments in other disease areas by the end of the decade. “In the year to date we have continued to make encouraging progress with several disruptive technologies … all of which have the potential to drive our growth beyond 2030,” CEO Soriot said in a statement. At its investor day in May, the company announced it aimed to grow revenue by about 75 per cent to $80 billion by 2030, citing the expected launch of 20 new medicines and growth in its cancer, biopharmaceuticals and rare disease portfolio. The company has been investing in building its pipeline and marketing new launches. In May, AstraZeneca said that a plant in Qingdao, China, will help it build a distinct local supply chain to serve the Chinese market, its second largest globally. Total revenue rose 17 per cent on a constant-currency basis to $12.94 billion for the three months ended June, while core earnings came in at $1.98 per share, compared with analysts’ average expectation of $12.6 billion and $1.98 per share, respectively, according to a company-compiled consensus. Source: Pharma

July 25,2024 London: The world just experienced the hottest day on record and prolonged heat waves have become more common due to climate change, conditions that can alter medications and their effects on patients taking them. Here is what you need to know about medicines in hot weather: Medications for common conditions can increase patients’ sensitivity to heat by impairing the body’s response to high temperatures, including the ability to sweat and the rate of blood flow. Heat waves also increase the risk of deterioration for nearly all medications, whether capsules, sprays, tablets, syrups, or some other form, if they are not kept within a certain temperature range. The heat-related effects of medications can vary based on individual health status, dosage and environmental conditions. Patients should consult their physicians about potentially adjusting doses or scheduling in hot weather, and they should keep cool by staying hydrated, carrying fans, and seeking shade or air conditioning, experts say. Blood pressure and heart failure medications: Angiotensin converting enzyme (ACE) inhibitors suppress thirst, making it harder to know when to drink more water and increasing the risk of dehydration. Calcium channel blockers can cause mineral imbalances, making it harder for the body to regulate its temperature, while beta blockers can make it harder to sweat and keep the body cool. Diuretics, or water pills, can also cause dehydration and mineral imbalances. Allergy medications: Some over-the-counter antihistamines reduce sweating and can impair temperature regulation. Psychiatric medications: Certain antipsychotic medications limit patients’ ability to sweat. Some antidepressants have the opposite effect, increasing sweating and repressing thirst. Stimulants such as amphetamines and other drugs used to treat attention deficit hyperactivity disorder may interact with the central nervous system to raise body temperature. Thyroid medications: Thyroid hormone pills also can raise body temperature, impair temperature regulation and cause excessive sweating. Extreme heat (and extreme cold) can significantly alter the effectiveness of prescription and over-the-counter drugs. Some medications can tolerate temperatures up to 86 degrees Fahrenheit (30 Celsius), but in general they should be stored at 59-77 F (15-77 C) in a cool, dry place, away from sunlight. Temperature storage guidelines for specific drugs can be found on manufacturers’ websites. It’s hard to predict the extent to which a medication will degrade in extreme temperatures because each drug is different, said Amy Bachyrycz, a pharmacy faculty member at the University of New Mexico in Albuquerque. In general, medicines should not be left in hot cars or for hours in hot mail boxes if they are mail-ordered medications. A spokesperson for CVS Health’s Caremark pharmacy benefits unit said the company’s electronic shipping system takes weather data into account to determine appropriate packaging materials for each shipment. An Amazon.com Pharmacy spokesperson said the company employs strict storage and delivery safety measures to protect medications from extreme temperatures throughout the shipping process. Source: Healthworld

July 25,2024 New Delhi: The Indian Council of Medical Research (ICMR), in collaboration with the National Health Authority (NHA) and WHO India, has released 32 new Standard Treatment Workflows (STWs) for common and serious diseases. The new STWs cover five specialties, including cardiothoracic vascular surgery, paediatric cardiology, interventional radiology, neurosurgery, and orthopaedics, adding to the 125 STWs previously released across 23 specialties in 2019 and 2022. During the Volume-IV launch of Standard Treatment Workflows at ICMR, Department of Health Research (DHR) Secretary and ICMR Director General Rajiv Bahl emphasised the significance of these protocols and said that these standard protocols save lives and improve the quality of care. “By incorporating these workflows into medical education from the beginning, we strengthen the foundation of our healthcare professionals . We also aim to disseminate these workflows to healthcare insurance companies, healthcare centres, central health systems, and medical professional bodies,” Rajiv Bahl said speaking on occasion. National Health Authority (NHA) Chief Executive Officer Deepti Gaur Mukerjee shared her positive outlook on the collaboration and highlighted future plans. “Our joint initiative with ICMR for the development of these workflows has been a fruitful endeavour. We’ve put considerable effort into broadening the specialties encompassed by the STWs. Looking forward, specialties such as burn management, plastic surgeries, and polytrauma will take centre stage in our future efforts. Our aim is to persistently enhance patient care by covering a more diverse range of medical fields through our STWs,” Deepti Gaur Mukerjee said. Endorsing the STWs, Member NITI Aayog Vinod Kumar Paul said, “These vital tools have been the guiding light since inception, shaping a resilient future. These evidence-based and trusted workflows ensure that patients receive the right treatment, while standardisation helps healthcare professionals follow guidelines effectively.” “Transformative and reliable, they guarantee accurate patient care. Standardisation empowers healthcare professionals to easily adhere to guidelines, ensuring effective treatment protocols for all. Let’s not just know but apply these STWs, instilling pride in India’s healthcare system,” VK Paul said. Senior Deputy Director General and Head Delivery Research at ICMR Ashoo Grover highlighted the impact of these STWs and said that the dissemination of the STWs has been remarkable, both nationally and internationally. “Our collaboration with National Institute of Health & Family Welfare (NIHFW) has resulted in the publication of three manuscripts in PubMed-indexed journals. The development of these workflows is a challenging process, aiming to streamline healthcare in India. By incorporating STWs into practice, physicians can provide targeted treatment, while the public gains confidence in the healthcare system,” he said. The ICMR introduces evidence-based STWs to enhance medical care consistency in India. These guidelines, created by national experts, promote optimal treatment practices, rational drug use, and efficient healthcare services. Each concise one-page document outlines key actions for physicians, ensuring uniform healthcare standards in India’s public healthcare system. The Indian Council of Medical Research (ICMR) remains committed to advancing standardised and evidence-based care through the development and implementation of the Standard Treatment Workflows (STWs). These workflows not only empower healthcare professionals but also ensure the provision of high-quality care to patients across the country. (ANI) Source: Healthworld

July 25,2024 Hyderabad: ETPharma will be hosting the second edition of the Next-Gen Lab-Con on July 26, 2024, at Le Meridien, Hyderabad. The conference aims to bring together industrial leaders to focus on the pharmaceutical landscape, which is rapidly evolving and to discuss what will be the future generation of pharma labs and their regulatory obligations. The second edition of ETPharma’s Next-Gen LabCon, themed ‘Future-Ready Labs: Analog to Digital’ will focus on the seamless progression of a product life cycle, heightened competition and building next-gen, future-ready pharma labs, which is crucial to fulfilling the demand for innovative therapies, enhancing approval rates, minimising expenses, accelerating time-to-market, and adhering to regulatory obligations. The conclave will commence with a welcome address by Vikas Dandekar, Editor, ETPharma, followed by the Chief Guest’s address on the topic ‘Navigating the future of Pharmaceutical Exports: Quality Imperatives and Global Compliance’ by Raja Bhanu, Director General, Pharmexcil. The Chief Guest’s address will be followed by a panel discussion on ‘Indian Laboratories – what does it take, to take it to a global scale?’. The panellists for the session will be Annaswamy Vaidheesh, Executive Chairperson, Suven Pharma; Dr KVS Ram Rao, CEO & Joint Managing Director, Granules India, Akhil Ravi, Chief Executive Officer, Aurigene Pharmaceutical Services, and Dr Sauri Gudlavalleti, Chief Operating Officer, Sai Lifesciences. The session will be moderated by Vikas Dandekar, Editor, ETPharma. The session on ‘Indian Laboratories – what does it take, to take it to a global scale? will be followed by a panel discussion on ‘Role of Sensors, AI, ML, RPA in Enhancing R&D Experimentation’. The panellists for the session will be Dr Mandar Ghatnekar, Global Head of IT & Digital Transformation , Biocon Biologics; Chitti Babu, Chief Information Officer (CIO), Aurobindo Pharma; Rithesh Phalaksha, Director – Leading Digital Innovation, Novartis; and Dr Sujay Rajhans, President, Head R&D, JB Pharma. The session will be moderated by Chakravarthi AVPS, Chairman, Federation of Pharma Entrepreneurs – Telangana & Andhra Pradesh, FOPE South. The panel discussion on ‘Role of Sensors, AI, ML, RPA in Enhancing R&D Experimentation’ will be followed by a case study on Gen AI by Tushar Zade, CDO & CIO, Aurigene Pharmaceuticals Services Ltd. The Gen AI case study will be followed by a panel discussion on ‘Ask the Experts- Upscaling to Electronic Batch Records: Lessons from a Pharmaceutical Manufacturer’. The panellists for the discussion include Dr Pavan Bhat, Executive Director, Natco Pharma, Sandeep Raktate, President – India & Ireland Operations, Amneal Pharmaceuticals. The session will be moderated by Vikas Dandekar, Editor, ETPharma. The ‘Ask the Experts- Upscaling to Electronic Batch Records: Lessons from a Pharmaceutical Manufacturer’ session will be followed by another panel discussion on ‘Implementing Green Chemistry Principles in CDMO Operations: A Sustainable Digital Transformation Journey’. The panellists for the dialogue include Dr Vijayavitthal T Mathad, Chief Operating Officer, CRAMSN Research Park, Dr Damodharan Muniyandi, Chief Quality Officer, Global Quality & Regulatory Affairs, Sai Life Sciences Ltd; Dr Rakeshwar Bandichhor, Vice President and Head of Chemistry, API Process R&D, Dr Reddy’s Laboratories. The moderator for the session will be Ivy Louis, Board Member, Parenteral Drug Association (PDA Inc.); Director-Vienni Training & Consulting LLP. The conference will conclude with the closing remarks by Prabhat Prakash, Senior Digital Content Producer, ETPharma. Source: Pharma

July 26,2024 London: Humanity is suffering from an “extreme heat epidemic,” UN Secretary-General Antonio Guterres warned Thursday, calling for action to limit the impacts of heat waves intensified by climate change. “Billions of people are facing an extreme heat epidemic — wilting under increasingly deadly heat waves, with temperatures topping 50 degrees Celsius around the world,” he said. “That’s 122 degrees Fahrenheit. And halfway to boiling.” According to the European Copernicus network , July 21, 22 and 23 were the three hottest days ever recorded worldwide, with July 22 holding the absolute record of 17.16 degrees Celsius (62.9 degrees Fahrenheit). Guterres repeated his call for humanity to fight its “addiction” to fossil fuels. “Today, our focus is on the impact of extreme heat . But let’s not forget that there are many other devastating symptoms of the climate crisis: ever-more fierce hurricanes. Floods. Droughts. Wildfires. Rising sea levels. And the list goes on,” he said. “To tackle all these symptoms, we need to fight the disease. And the disease is the madness of incinerating our only home. The disease is the addiction to fossil fuels. The disease is climate inaction,” he stressed, calling in particular on G20 countries to take action. While 2023 was the hottest year on record, and 2024 could set a new record, temperatures well above 40C (104F) are increasingly common. In the space of a year, the 50C threshold has even been exceeded in at least 10 places, from Death Valley in the United States (53.9C on July 7) to Agadir in Morocco, and also in China and India. The intense heat, often less visible than other devastating impacts of climate change such as storms or floods, is nonetheless more deadly. This “silent killer” is responsible for around 489,000 deaths per year between 2000 and 2019, compared with 16,000 deaths per year from cyclones, according to the UN’s “Call to Action” document published on Thursday. Extremely high temperatures also have an economic impact, with the UN estimating economic losses from heat stress at work will reach $2.4 trillion in 2030. According to a report by the International Labor Organisation published on Thursday, more than 70 percent of workers were exposed to excessive heat in 2020, 8.8 percent more than in 2000. “The good news is that we can save lives and we can limit its impact,” Guterres said Thursday. The UN has called for the world community to first act to protect “the most vulnerable” — including young children, the elderly and also humanity’s poorest. In this context, early warning systems should include extreme heat, warning populations of the arrival of heat waves and informing them of the precautions to take, the document says. The call to action also recommends an “increase (to) equitable access to and scale up (of) low-carbon cooling.” This would involve investing in passive cooling systems — which include climate-sensitive urban design measures, reflective surfaces and natural cooling systems — and the phase-out of climate-warming gases that are used in many cooling systems. Source: Healthworld

July 26,2024 New Delhi: The WHO Regional Director for Southeast Asia, Saima Wazed, appealed to everyone on Thursday, July 25, to save lives and prevent the heartbreak of drowning on World Drowning Prevention Day. She said, “We join the global community in observing World Drowning Prevention Day, dedicated to raising awareness and accelerating action on global drowning prevention. The World Health Assembly Resolution WHA76.18, passed in 2023, underscores the urgent need for coordinated multi-sectoral action to combat this leading cause of injury-related death and disability worldwide.” Highlighting this year’s theme, “Anyone can drown, no one should,” she said, “This year, under the overarching theme “Anyone can drown, no one should,” the World Health Organisation has chosen the slogan “Seconds can save a life.” This highlights the dual nature of drowning: it can occur in a matter of seconds yet taking a brief moment to act–whether by wearing a lifejacket, keeping watch over children while they are near water, checking the weather forecast before boating, or choosing safety over distraction–can prevent a tragedy.”. “Drowning is a sudden and silent killer, often catching victims and those around them unaware until it is too late. A few seconds may not be enough time to respond. The power is in prevention,” she added. Globally, an estimated 236,000 lives are lost to drowning every year–an average of 650 every day, or 26 every hour. This silent epidemic of preventable deaths excludes drownings related to flood disasters and water transport incidents, thus underreporting the true magnitude of the issue. She further added, “In our Southeast Asia Region, the consequences of drowning are particularly devastating. In 2019 alone, drowning claimed 70,034 lives, making it the second-highest contributor to drowning deaths worldwide after the Western Pacific Region. Most of these tragedies occur within proximity of the home, primarily due to a lack of supervision, exposure to hazardous water bodies, a lack of awareness and education, as well as poverty.”. WHO is finalising the Global Status Report on Drowning, set to be launched by the end of 2024. This report will provide updated information on the global burden of drowning and will generate key recommendations for impactful actions at global, regional, and national levels. WHO has outlined evidence-based, cost-effective, and scalable measures to prevent drowning and provided detailed guidance for their implementation. While the application of these measures will vary by context, the global drowning prevention community must remain vigilant and coherent in its efforts. “We all have a role to play in preventing drowning. Whether by raising awareness, promoting knowledge of effective solutions, collaborating on prevention plans and policies with local or national governments, volunteering with relevant organisations, or ensuring personal and family safety around water, each of us can make a difference,” she added. (ANI) Source: Healthworld